Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

[Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].

ter Meulen CG, Hilbrands LB, van Riemsdijk-van Overbeeke IC, Hené RJ, Christiaans MH, Hoitsma AJ.

Ned Tijdschr Geneeskd. 2000 Dec 9;144(50):2396-400. Review. Dutch.

PMID:
11145094
2.
3.

Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.

Aktas S, Colak T, Baskin E, Sevmis S, Ozdemir H, Moray G, Karakayali H, Haberal M.

Transplant Proc. 2011 Mar;43(2):453-7. doi: 10.1016/j.transproceed.2011.01.075.

PMID:
21440732
4.

Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.

Lin M, Ming A, Zhao M.

Clin Transplant. 2006 May-Jun;20(3):325-9.

PMID:
16824149
5.

Efficacy and Safety of Basiliximab Versus Daclizumab in Kidney Transplantation: A Meta-Analysis.

Sun ZJ, Du X, Su LL, Zhang XD, Wang W.

Transplant Proc. 2015 Oct;47(8):2439-45. doi: 10.1016/j.transproceed.2015.08.009.

PMID:
26518947
6.

[Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].

Madsen M, Svendsen UG.

Ugeskr Laeger. 2000 Oct 16;162(42):5648-52. Review. Danish.

PMID:
11059309
7.

Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.

Nair MP, Nampoory MR, Johny KV, Costandi JN, Abdulhalim M, El-Reshaid W, Al-Muzairai I, Ninan VT, Samhan M, Al-Mousawi M.

Transplant Proc. 2001 Aug;33(5):2767-9. No abstract available.

PMID:
11498153
8.

Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.

Gabardi S, Catella J, Martin ST, Perrone R, Chandraker A, Magee CC, McDevitt-Potter LM.

Ann Pharmacother. 2011 Sep;45(9):e48. doi: 10.1345/aph.1Q019. Epub 2011 Aug 2.

PMID:
21811001
9.

Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.

Pascual J, Marcén R, Ortuño J.

Nephrol Dial Transplant. 2001 Sep;16(9):1756-60. Review. No abstract available.

PMID:
11522853
10.

Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.

Wiseman LR, Faulds D.

Drugs. 1999 Dec;58(6):1029-42. Review. Erratum in: Drugs 2000 Mar;59(3):476.

PMID:
10651389
11.

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.

Nashan B, Light S, Hardie IR, Lin A, Johnson JR.

Transplantation. 1999 Jan 15;67(1):110-5.

PMID:
9921806
12.

Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.

Pham K, Kraft K, Thielke J, Oberholzer J, Sankary H, Testa G, Benedetti E.

Transplant Proc. 2005 Mar;37(2):899-902.

PMID:
15848569
13.

Basiliximab: efficacy and safety evaluation in kidney transplantation.

Ponticelli C.

Expert Opin Drug Saf. 2014 Mar;13(3):373-81. doi: 10.1517/14740338.2014.861816. Epub 2013 Nov 25.

PMID:
24266670
14.

Daclizumab.

Mottershead M, Neuberger J.

Expert Opin Biol Ther. 2007 Oct;7(10):1583-96. Review.

PMID:
17916050
15.

New monoclonal antibodies to prevent transplant rejection.

[No authors listed]

Med Lett Drugs Ther. 1998 Sep 25;40(1036):93-4. No abstract available.

PMID:
9774964
16.

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.

Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J.

N Engl J Med. 1998 Jan 15;338(3):161-5.

17.

Induction immunotherapy with IL-2Ra monoclonal antibody in kidney transplantation.

Ahsan N.

Minerva Urol Nefrol. 2003 Mar;55(1):67-79. Review.

PMID:
12773968
18.

Use of basiliximab and daclizumab in kidney transplantation.

Olyaei AJ, Thi K, deMattos AM, Bennett WM.

Prog Transplant. 2001 Mar;11(1):33-7; quiz 38-9. Review.

PMID:
11357555
19.

Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies.

Crins ND, Röver C, Goralczyk AD, Friede T.

Pediatr Transplant. 2014 Dec;18(8):839-50. doi: 10.1111/petr.12362. Epub 2014 Oct 4. Review.

20.

A review of interleukin-2 receptor antagonists in solid organ transplantation.

Berard JL, Velez RL, Freeman RB, Tsunoda SM.

Pharmacotherapy. 1999 Oct;19(10):1127-37. Review.

PMID:
10512062

Supplemental Content

Support Center